Skip to main content

TCR2 Therapeutics Inc.

TCRRDelisted Jun 1, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001750019

TCR2 Therapeutics Inc. was delisted on Jun 1, 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.5M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding TCR2 Therapeutics Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of TCRR: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders119117−2
Shares35.1M31.8M−3.22M (−9.2%)
Value$575.3M$271.1M−$304.2M (−52.9%)

New holders (18)

Institutions that held TCR2 Therapeutics Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to TCRR in Q3 2021
InstitutionSharesValue% of portfolio
Marshall Wace North America L.P.543,582$4.63M0.02%
Ghost Tree Capital, LLC477,323$4.06M1.34%
Schonfeld Strategic Advisors LLC241,761$2.06M0.02%
Marshall Wace, LLP187,433$1.59M0.01%
Caas Capital Management LP147,600$1.26M0.09%
SG3 Management, LLC114,844$977.0K0.35%
Caption Management, LLC71,283$607.0K0.04%
Oppenheimer & Co Inc48,700$414.0K0.01%
PDT Partners, LLC25,419$216.0K0.02%
Connor, Clark & Lunn Investment Management Ltd.24,317$207.0K0.00%
Walleye Trading LLC21,474$183.0K0.00%
Fox Run Management, L.L.C.13,556$115.0K0.07%
Ergoteles LLC13,100$111.0K0.00%
Jane Street Group, LLC11,193$95.0K0.00%
Macquarie Group Ltd3,580$30.0K0.00%
Quantbot Technologies LP3,300$28.0K0.00%
Federation des caisses Desjardins du Quebec250$2.13K0.00%
Signaturefd, LLC103$1.00K0.00%

Sold out (20)

Institutions that held TCR2 Therapeutics Inc. at the end of Q2 2021 and filed for Q3 2021 without it.